DeepUll


Developer of automated direct-from-blood molecular diagnostic technology for rapid identification of bloodstream pathogens and antibiotic-resistance markers. The company is developing an automated sample-to-result platform that extracts total microbial DNA from whole blood and aims to deliver a broad panel of pathogen and resistance results in about 1 hour. Products are under development and not currently available for diagnostic use.

Industries

biotechnology
life-science

Nr. of Employees

small (1-50)

DeepUll

Barcelona, Catalonia, Spain, Europe


Products

Automated direct-from-blood molecular diagnostic system (prototype)

Automated instrument that extracts total microbial DNA from whole blood and runs a molecular assay to identify pathogens and resistance markers with an intended ~1-hour turnaround. Designed for continuous loading (up to 8 samples), STAT prioritization, and LIS connectivity.

Direct-from-blood bloodstream infection (BSI) molecular test (prototype)

Assay designed for use with whole blood (8 mL) to detect a broad panel of sepsis-causing pathogens and antibiotic resistance markers; preliminary data show higher pathogen detection compared to blood culture and high concordance with positive cultures.

Expertise Areas

  • Direct-from-blood molecular diagnostics
  • Sepsis and bloodstream infection testing
  • Automated sample-to-answer diagnostic platforms
  • Microbial cell-free DNA analysis
  • Show More (4)

Key Technologies

  • Multiplex PCR
  • Total microbial DNA extraction from whole blood
  • Microbial cell-free DNA detection
  • Automated sample-to-result instrumentation
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.